PL1614419T3 - Środek zapobiegawczy/lek przeciwko chorobom nerwu wzrokowego zawierający pochodne eteru alkilowego lub ich sole - Google Patents
Środek zapobiegawczy/lek przeciwko chorobom nerwu wzrokowego zawierający pochodne eteru alkilowego lub ich soleInfo
- Publication number
- PL1614419T3 PL1614419T3 PL04727697T PL04727697T PL1614419T3 PL 1614419 T3 PL1614419 T3 PL 1614419T3 PL 04727697 T PL04727697 T PL 04727697T PL 04727697 T PL04727697 T PL 04727697T PL 1614419 T3 PL1614419 T3 PL 1614419T3
- Authority
- PL
- Poland
- Prior art keywords
- remedy
- preventive
- salts
- alkyl ether
- containing alkyl
- Prior art date
Links
- 150000005215 alkyl ethers Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000005036 nerve Anatomy 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 230000002207 retinal effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003112539 | 2003-04-17 | ||
| EP04727697A EP1614419B1 (en) | 2003-04-17 | 2004-04-15 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| PCT/JP2004/005355 WO2004091605A1 (ja) | 2003-04-17 | 2004-04-15 | アルキルエーテル誘導体またはその塩を含有する網膜神経疾患の予防・治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1614419T3 true PL1614419T3 (pl) | 2013-01-31 |
Family
ID=33296058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04727697T PL1614419T3 (pl) | 2003-04-17 | 2004-04-15 | Środek zapobiegawczy/lek przeciwko chorobom nerwu wzrokowego zawierający pochodne eteru alkilowego lub ich sole |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20060205709A1 (pl) |
| EP (1) | EP1614419B1 (pl) |
| JP (1) | JP4642657B2 (pl) |
| KR (1) | KR101096528B1 (pl) |
| CN (1) | CN100353942C (pl) |
| AU (1) | AU2004229283B2 (pl) |
| BR (1) | BRPI0409398A (pl) |
| CA (1) | CA2521648C (pl) |
| CY (1) | CY1113248T1 (pl) |
| DK (1) | DK1614419T3 (pl) |
| ES (1) | ES2391273T3 (pl) |
| IL (1) | IL171388A (pl) |
| MX (1) | MXPA05011125A (pl) |
| NO (1) | NO334062B1 (pl) |
| NZ (1) | NZ543100A (pl) |
| PL (1) | PL1614419T3 (pl) |
| PT (1) | PT1614419E (pl) |
| SI (1) | SI1614419T1 (pl) |
| WO (1) | WO2004091605A1 (pl) |
| ZA (1) | ZA200508166B (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2287324T3 (es) * | 2001-10-19 | 2007-12-16 | Toyama Chemical Co., Ltd. | Derivados de alquil eter o sus sales. |
| KR100935615B1 (ko) | 2002-06-14 | 2010-01-07 | 토야마 케미칼 컴퍼니 리미티드 | 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법 |
| RU2397169C2 (ru) * | 2005-03-28 | 2010-08-20 | Тояма Кемикал Ко., Лтд. | Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей |
| EP1864978A4 (en) * | 2005-03-28 | 2009-07-01 | Toyama Chemical Co Ltd | PROCESS FOR PREPARING 1- (3- (2- (1-BENZOTHIOPHEN-5-YL) ETHOXY) PROPYL) AZETIDIN-3-OL OR SALTS THEREOF |
| SI2011796T1 (sl) * | 2006-04-26 | 2015-02-27 | Toyama Chemical Co., Ltd. | Induktor nevrogeneze ali terapevtska uäśinkovina proti nevropatiji, vsebujoäśa derivat alkilnega etra ali sol le-tega |
| US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| DK2048145T3 (da) * | 2006-08-04 | 2011-04-04 | Toyama Chemical Co Ltd | Forstærker af aktiviteten af proteinkinase C indeholdende alkyletherderivat eller et salt deraf |
| MY155612A (en) | 2008-07-14 | 2015-11-13 | Biocon Ltd | A method of synthesizing a substantially monodispersed mixture of oligomers |
| BR112014020434B1 (pt) * | 2012-02-22 | 2021-10-13 | Fujifilm Toyama Chemical Co., Ltd. | Composição farmacêutica sólida |
| WO2015115582A1 (ja) | 2014-01-31 | 2015-08-06 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤 |
| WO2016199878A1 (ja) * | 2015-06-11 | 2016-12-15 | 富山化学工業株式会社 | シグマ受容体結合剤 |
| DK3395342T3 (da) | 2015-12-25 | 2020-10-12 | Fujifilm Toyama Chemical Co Ltd | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf |
| US20190343796A1 (en) | 2016-12-28 | 2019-11-14 | Fujifilm Toyama Chemical Co., Ltd. | Composition for external use |
| JPWO2018221728A1 (ja) | 2017-06-02 | 2020-04-02 | 富士フイルム富山化学株式会社 | アルツハイマー型認知症予防または治療剤 |
| AU2018277981B2 (en) | 2017-06-02 | 2021-04-08 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating spinocerebellar ataxia |
| SG11201911512SA (en) | 2017-06-02 | 2020-01-30 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating brain atrophy |
| EP3632429A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR REDUCING AMYLOID PROTEIN CONTENT |
| WO2019088083A1 (ja) | 2017-10-30 | 2019-05-09 | 富士フイルム富山化学株式会社 | エモパミル結合タンパク質結合剤およびその利用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521136A1 (fr) * | 1982-02-05 | 1983-08-12 | Synthelabo | Derives de piperidine, leur preparation et leur application en therapeutique |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| DK74693D0 (da) * | 1993-06-23 | 1993-06-23 | Novo Nordisk As | Novel heterocyclic chemistry |
| TW281667B (pl) | 1994-02-03 | 1996-07-21 | Synthelabo | |
| AU7001796A (en) * | 1995-09-22 | 1997-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
| JP4549452B2 (ja) * | 1997-12-12 | 2010-09-22 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤 |
| CA2424585A1 (en) * | 2000-10-10 | 2003-04-02 | Toyama Chemical Co., Ltd. | Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof |
| JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| ES2287324T3 (es) * | 2001-10-19 | 2007-12-16 | Toyama Chemical Co., Ltd. | Derivados de alquil eter o sus sales. |
| KR100935615B1 (ko) * | 2002-06-14 | 2010-01-07 | 토야마 케미칼 컴퍼니 리미티드 | 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법 |
-
2004
- 2004-04-15 DK DK04727697.7T patent/DK1614419T3/da active
- 2004-04-15 ZA ZA200508166A patent/ZA200508166B/en unknown
- 2004-04-15 CN CNB2004800103801A patent/CN100353942C/zh not_active Expired - Fee Related
- 2004-04-15 AU AU2004229283A patent/AU2004229283B2/en not_active Ceased
- 2004-04-15 SI SI200431955T patent/SI1614419T1/sl unknown
- 2004-04-15 NZ NZ543100A patent/NZ543100A/en not_active IP Right Cessation
- 2004-04-15 CA CA2521648A patent/CA2521648C/en not_active Expired - Fee Related
- 2004-04-15 EP EP04727697A patent/EP1614419B1/en not_active Expired - Lifetime
- 2004-04-15 BR BRPI0409398-4A patent/BRPI0409398A/pt not_active Application Discontinuation
- 2004-04-15 PT PT04727697T patent/PT1614419E/pt unknown
- 2004-04-15 JP JP2005505437A patent/JP4642657B2/ja not_active Expired - Fee Related
- 2004-04-15 PL PL04727697T patent/PL1614419T3/pl unknown
- 2004-04-15 MX MXPA05011125A patent/MXPA05011125A/es unknown
- 2004-04-15 US US10/553,120 patent/US20060205709A1/en not_active Abandoned
- 2004-04-15 ES ES04727697T patent/ES2391273T3/es not_active Expired - Lifetime
- 2004-04-15 WO PCT/JP2004/005355 patent/WO2004091605A1/ja not_active Ceased
- 2004-04-15 KR KR1020057019794A patent/KR101096528B1/ko not_active Expired - Fee Related
-
2005
- 2005-10-11 IL IL171388A patent/IL171388A/en not_active IP Right Cessation
- 2005-10-20 NO NO20054855A patent/NO334062B1/no not_active IP Right Cessation
-
2009
- 2009-08-17 US US12/542,074 patent/US7897594B2/en not_active Expired - Fee Related
-
2011
- 2011-01-19 US US13/008,982 patent/US8067406B2/en not_active Expired - Fee Related
-
2012
- 2012-10-23 CY CY20121100992T patent/CY1113248T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054855D0 (no) | 2005-10-20 |
| CN100353942C (zh) | 2007-12-12 |
| NO334062B1 (no) | 2013-12-02 |
| ES2391273T3 (es) | 2012-11-23 |
| KR20050123167A (ko) | 2005-12-29 |
| CA2521648A1 (en) | 2004-10-28 |
| EP1614419A1 (en) | 2006-01-11 |
| US20110112066A1 (en) | 2011-05-12 |
| AU2004229283B2 (en) | 2009-02-05 |
| MXPA05011125A (es) | 2005-12-14 |
| JPWO2004091605A1 (ja) | 2006-07-06 |
| IL171388A (en) | 2010-12-30 |
| US20060205709A1 (en) | 2006-09-14 |
| PT1614419E (pt) | 2012-10-22 |
| NO20054855L (no) | 2006-01-09 |
| ZA200508166B (en) | 2007-03-28 |
| US8067406B2 (en) | 2011-11-29 |
| CN1774245A (zh) | 2006-05-17 |
| CA2521648C (en) | 2012-07-03 |
| DK1614419T3 (da) | 2012-11-19 |
| EP1614419A4 (en) | 2010-08-18 |
| BRPI0409398A (pt) | 2006-04-18 |
| KR101096528B1 (ko) | 2011-12-20 |
| SI1614419T1 (sl) | 2012-12-31 |
| US20100075941A1 (en) | 2010-03-25 |
| US7897594B2 (en) | 2011-03-01 |
| NZ543100A (en) | 2008-07-31 |
| EP1614419B1 (en) | 2012-08-08 |
| WO2004091605A1 (ja) | 2004-10-28 |
| CY1113248T1 (el) | 2016-04-13 |
| JP4642657B2 (ja) | 2011-03-02 |
| AU2004229283A1 (en) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1614419T3 (pl) | Środek zapobiegawczy/lek przeciwko chorobom nerwu wzrokowego zawierający pochodne eteru alkilowego lub ich sole | |
| GB0312832D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| SI1656347T1 (sl) | Substituirani indolni derivati za farmacevtske sestavke za zdravljenje respiratornih bolezni | |
| AU2003291992A1 (en) | Phenylethanolamine derivatives for the treatment of respiratory diseases | |
| AP2037A (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| IL176629A0 (en) | Sulfonamide derivatives for the treatment of diseases | |
| IL176397A0 (en) | Pharmaceutical compositions containing hyaluronidase or collagenase for treatment of ophthalmic conditions | |
| EP1568380A4 (en) | PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA | |
| AP2006003669A0 (en) | Sulfonamide derivatives for the treatment of diseases | |
| AP1959A (en) | The use of N-arylhydrazine derivatives for combating pests | |
| GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
| PL1732558T3 (pl) | Pochodne 1-[2H-1-benzopiran-2-on-8-ylo]-piperazyny do leczenia bólu | |
| EP1566184A4 (en) | REMEDY FOR THE TREATMENT OF CORNEAL DISEASE | |
| PL1732557T3 (pl) | Pochodne 1-[2H-1-benzopiran-2-on-8-ylo]-piperazyny do leczenia zaburzeń ruchowych | |
| IL172377A0 (en) | 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders | |
| PT1594498E (pt) | Utilização de etazolato para o tratamento de patologias oculares neurodegenerativas | |
| ZA200606780B (en) | Compounds for the treatment of diseases | |
| GB0312842D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| GB0312840D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| EP1666068A4 (en) | REMEDY FOR EYE DISEASES ACCOMPANIED BY OPTICAL NERVE INJURIES | |
| PL371756A1 (pl) | N1-Arylopiperazynoalkilo pochodne 5,5-difenylohydantoiny | |
| EP1626044A4 (en) | NEW PIPERIDINE DERIVATIVE | |
| AU2003300147A1 (en) | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | |
| IL176564A0 (en) | Sulfonamide derivatives for the treatment of diseases | |
| GB0406388D0 (en) | Sulfonamide derivatives for the treatment of diseases |